HRP20230306T1 - Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori - Google Patents

Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori Download PDF

Info

Publication number
HRP20230306T1
HRP20230306T1 HRP20230306TT HRP20230306T HRP20230306T1 HR P20230306 T1 HRP20230306 T1 HR P20230306T1 HR P20230306T T HRP20230306T T HR P20230306TT HR P20230306 T HRP20230306 T HR P20230306T HR P20230306 T1 HRP20230306 T1 HR P20230306T1
Authority
HR
Croatia
Prior art keywords
methyl
tetrahydro
imidazo
cancer
membered
Prior art date
Application number
HRP20230306TT
Other languages
English (en)
Inventor
Liangxing Wu
Kaijiong Xiao
Wenqing Yao
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66625434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20230306(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corporation filed Critical Incyte Corporation
Publication of HRP20230306T1 publication Critical patent/HRP20230306T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (21)

1. Spoj, naznačen time, da je predstavljen Formulom I: [image] ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, pri čemu: R1 je metil, CN, F, Cl, ili Br; R2 je metil, CN, F, Cl, ili Br; i R3 je H, C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril, 5-člani do 6-člani heteroaril-C1-2 alkil, 4-člani do 6-člani heterocikloalkil ili 4-člani do 6-člani heterocikloalkil-C1-2 alkil-, gdje svaki 5-člani do 6-člani heteroaril, 5-člani do 6-člani heteroaril-C1-2 alkil, 4-člani do 6-člani heterocikloalkil i 4-člani do 6-člani heterocikloalkil-C1-2 alkil-, ima jedan ili dva heteroatoma kao članove u prstenu, odabrane od O, N i S, i pri čemu je svaki C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril, 5-člani do 6-člani heteroaril-C1-2 alkil, 4-člani do 6-člani heterocikloalkil i 4-člani do 6-člani heterocikloalkil-C1-2 alkil- od R3, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2, COOH, OH, CON(CH3)2, CH3, F, Cl, Br, CN, etila, i propila.
2. Spoj prema patentnom zahtjevu 1, naznačen time, da ima Formulu I: [image] ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, pri čemu: R1 je metil, CN, F, Cl, ili Br; R2 je metil, CN, F, Cl, ili Br; i R3 je H, C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril, 5-člani do 6-člani heteroaril-C1-2 alkil, 4-člani do 6-člani heterocikloalkil ili 4-člani do 6-člani heterocikloalkil-C1-2 alkil-, gdje svaki 5-člani do 6-člani heteroaril, 5-člani do 6-člani heteroaril-C1-2 alkil, 4-člani do 6-člani heterocikloalkil i 4-člani do 6-člani heterocikloalkil-C1-2 alkil-, ima jedan ili dva heteroatoma kao članove u prstenu, odabrane od O, N i S, i pri čemu je svaki C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril, 5-člani do 6-člani heteroaril-C1-2 alkil, 4-člani do 6-člani heterocikloalkil i 4-člani do 6-člani heterocikloalkil-C1-2 alkil- od R3, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2, COOH, i OH.
3. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, naznačen time, da: (a) R1 je metil, F, Cl, ili Br; ili (b) R1 je metil; ili (c) R1 je F, Cl, ili Br; ili (d) R1 je Cl.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, naznačen time, da: (a) R2 je metil; ili (b) R2 je CN; ili (c) R2 je F, Cl, ili Br; ili (d) R2 je Cl.
5. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, naznačen time, da: (a) R1 je Cl i R2 je Cl; ili (b) R1 je Cl i R2 je metil; ili (c) R1 je metil i R2 je Cl; ili (d) R1 je Cl i R2 je CN; ili (e) R1 je metil i R2 je metil.
6. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, naznačen time, da: (a) R3 je H, C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, ili 4-člani do 6-člani heterocikloalkil, gdje svaki 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil, ima jedan ili dva heteroatoma kao članove u prstenu, odabrane od O, N i S, i pri čemu je svaki C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil od R3, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2, COOH, OH, CON(CH3)2, i CH3; ili (b) R3 je C1-4 alkil, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od COOH, OH, i CON(CH3)2; ili (c) R3 je C3-8 cikloalkil, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od COOH, OH, i CH3; ili (d) R3 je ciklobutil, 4-hidroksicikloheksil, (1-karboksiciklopropil)metil, (4-karboksibiciklo[2.2.1]heptan-1-il)etil, (4-karboksibiciklo[2.2.1]heptan-1-il)metil, (4-karboksibiciklo[2.2.2]oktan-1-il)metil, (3-karboksibiciklo[1.1.1]pentan-1-il)metil, 4-karboksifenetil, (4-karboksicikloheksil)etil, ili 4-karboksi-4-metilcikloheksil; ili (e) R3 je H, metil, etil, izopropil, 1,3-dihidroksipropan-2-il, 2,3-dihidroksipropil, 2-hidroksipropil, 2-hidroksietil, 3-hidroksipropil, karboksimetil, 3-karboksipropil, 2-karboksi-2-metilpropil, ciklobutil, 4-hidroksicikloheksil, (1-karboksiciklopropil)metil, (4-karboksibiciklo[2.2.1]heptan-1-il)etil, (4-karboksibiciklo[2.2.1]heptan-1-il)metil, (4-karboksibiciklo[2.2.2]oktan-1-il)metil, (3-karboksibiciklo[1.1.1]pentan-1-il)metil, 4-karboksifenetil, (1H-pirazol-3-il)metil, tetrahidro-2H-piran-4-il, 1-karbamoilpiperidin-4-il, 1-sulfamoilpiperidin-4-il, (3-karboksi-1H-pirazol-5-il)metil, 4-karboksibutil, (4-karboksicikloheksil)etil, ili 4-karboksi-4-metilcikloheksil.
7. Spoj prema bilo kojem od patentnih zahtjeva 1-5, ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, naznačen time, da: (a) R3 je H, C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, ili 4-člani do 6-člani heterocikloalkil, gdje svaki 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil, ima jedan ili dva heteroatoma kao članove u prstenu, odabrane od O, N i S, i pri čemu je svaki C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil od R3, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2, COOH, i OH; ili (b) R3je H; ili (c) R3 je C1-4 alkil, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od COOH i OH; ili (d) R3 je metil, etil, izopropil, 1,3-dihidroksipropan-2-il, 2,3-dihidroksipropil, 2-hidroksipropil, 2-hidroksietil, 3-hidroksipropil, karboksimetil, 3-karboksipropil, 2-karboksi-2-metilpropil, ili 4-karboksibutil; ili (e) R3 je metil, etil, izopropil, 1,3-dihidroksipropan-2-il, 2,3-dihidroksipropil, 2-hidroksipropil, 2-hidroksietil, 3-hidroksipropil, karboksimetil, 3-karboksipropil, ili 2-karboksi-2-metilpropil; ili (f) R3 je C3-8cikloalkil, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od COOH i OH; ili (g) R3 je C3-8 cikloalkil-C1-2 alkil-, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od COOH i OH; ili (h) R3 je C6-10 aril-C1-2 alkil, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od COOH i OH; ili (i) R3 je ciklobutil, 4-hidroksicikloheksil, (1-karboksiciklopropil)metil, (4-karboksibiciklo[2.2.1]heptan-1-il)etil, (4-karboksibiciklo[2.2.1]heptan-1-il)metil, (4-karboksibiciklo[2.2.2]oktan-1-il)metil, (3-karboksibiciklo[1.1.1]pentan-1-il)metil, ili 4-karboksifenetil; ili (j) R3 je 5-člani do 6-člani heteroaril-C1-2 alkil, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2 i COOH; ili (k) R3 je 4-člani do 6-člani heterocikloalkil, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2 i COOH; ili (l) R3 je (1H-pirazol-3-il)metil, tetrahidro-2H-piran-4-il, 1-karbamoilpiperidin-4-il, 1-sulfamoilpiperidin-4-il, ili (3-karboksi-1H-pirazol-5-il)metil; ili (m) R3 je H, metil, etil, izopropil, 1,3-dihidroksipropan-2-il, 2,3-dihidroksipropil, 2-hidroksipropil, 2-hidroksietil, 3-hidroksipropil, karboksimetil, 3-karboksipropil, 2-karboksi-2-metilpropil, ciklobutil, 4-hidroksicikloheksil, (1-karboksiciklopropil)metil, (4-karboksibiciklo[2.2.1]heptan-1-il)etil, (4-karboksibiciklo[2.2.1]heptan-1-il)metil, (4-karboksibiciklo[2.2.2]oktan-1-il)metil, (3-karboksibiciklo[1.1.1]pentan-1-il)metil, 4-karboksifenetil, (1H-pirazol-3-il)metil, tetrahidro-2H-piran-4-il, 1-karbamoilpiperidin-4-il, 1-sulfamoilpiperidin-4-il, ili (3-karboksi-1H-pirazol-5-il)metil.
8. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, naznačen time, da: (a) R1 je metil, CN, F, Cl, ili Br; R2 je metil, CN, F, Cl, ili Br; i R3 je H, C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, ili 4-člani do 6-člani heterocikloalkil, gdje svaki 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil, ima jedan ili dva heteroatoma kao članove u prstenu, odabrane od O, N i S, i pri čemu je svaki C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil od R3, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2, COOH, OH, CON(CH3)2, i CH3; ili (b) R1 je metil, CN, F, Cl, ili Br; R2 je metil, CN, F, Cl, ili Br; i R3 je H, C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, ili 4-člani do 6-člani heterocikloalkil, gdje svaki 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil, ima jedan ili dva heteroatoma kao članove u prstenu, odabrane od O, N i S, i pri čemu je svaki C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil od R3, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2, COOH, i OH; ili (c) R1 je metil, ili Cl; R2 je metil, CN, ili Cl; i R3 je H, C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, ili 4-člani do 6-člani heterocikloalkil, gdje svaki 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil, ima jedan ili dva heteroatoma kao članove u prstenu, odabrane od O, N i S, i pri čemu je svaki C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil od R3, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2, COOH, OH, CON(CH3)2, i CH3; ili (d) R1 je metil, ili Cl; R2 je metil, CN, ili Cl; i R3 je H, C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, ili 4-člani do 6-člani heterocikloalkil, gdje svaki 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil, ima jedan ili dva heteroatoma kao članove u prstenu, odabrane od O, N i S, i pri čemu je svaki C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil od R3, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2, COOH, i OH; ili (e) R1 je metil, ili Cl; R2 je metil, CN, ili Cl; i R3 je H, metil, etil, izopropil, 1,3-dihidroksipropan-2-il, 2,3-dihidroksipropil, 2-hidroksipropil, 2-hidroksietil, 3-hidroksipropil, karboksimetil, 3-karboksipropil, 2-karboksi-2-metilpropil, ciklobutil, 4-hidroksicikloheksil, (1-karboksiciklopropil)metil, (4-karboksibiciklo[2.2.1]heptan-1-il)etil, (4-karboksibiciklo[2.2.1]heptan-1-il)metil, (4-karboksibiciklo[2.2.2]oktan-1-il)metil, (3-karboksibiciklo[1.1.1]pentan-1-il)metil, 4-karboksifenetil, (1H-pirazol-3-il)metil, tetrahidro-2H-piran-4-il, 1-karbamoilpiperidin-4-il, 1-sulfamoilpiperidin-4-il, (3-karboksi-1H-pirazol-5-il)metil, 4-karboksibutil, (4-karboksicikloheksil)etil, ili 4-karboksi-4-metilcikloheksil; ili (f) R1 je metil, ili Cl; R2 je metil, CN, ili Cl; i R3 je H, metil, etil, izopropil, 1,3-dihidroksipropan-2-il, 2,3-dihidroksipropil, 2-hidroksipropil, 2-hidroksietil, 3-hidroksipropil, karboksimetil, 3-karboksipropil, 2-karboksi-2-metilpropil, ciklobutil, 4-hidroksicikloheksil, (1-karboksiciklopropil)metil, (4-karboksibiciklo[2.2.1]heptan-1-il)etil, (4-karboksibiciklo[2.2.1]heptan-1-il)metil, (4-karboksibiciklo[2.2.2]oktan-1-il)metil, (3-karboksibiciklo[1.1.1]pentan-1-il)metil, 4-karboksifenetil, (1H-pirazol-3-il)metil, tetrahidro-2H-piran-4-il, 1-karbamoilpiperidin-4-il, 1-sulfamoilpiperidin-4-il, ili (3-karboksi-1H-pirazol-5-il)metil.
9. Spoj prema patentnom zahtjevu 1, naznačen time, da se spoj bira od sljedećih: (a) 4-(2-(2-((2,2'-dikloro-3'-(1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(1-metil-5-(tetrahidro-2H-piran-4-il)-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(1,5-dimetil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(5-etil-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(5-izopropil-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(5-ciklobutil-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(1-karbamoilpiperidin-4-il)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(1-metil-5-(1-sulfamoilpiperidin-4-il)-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-((1H-pirazol-3-il)metil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(5-(1,3-dihidroksipropan-2-il)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (R)-4-(2-(2-((2,2'-dikloro-3'-(5-(2,3-dihidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (S)-4-(2-(2-((2,2'-dikloro-3'-(5-(2,3-dihidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (R)-4-(2-(2-((2,2'-dikloro-3'-(5-(2-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (S)-4-(2-(2-((2,2'-dikloro-3'-(5-(2-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(5-(2-hidroksietil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(5-(3-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4,4'-(((((2,2'-dikloro-[1,1'-bifenil]-3,3'-diil)bis(azandiil))bis(karbonil))bis(1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-2,5-diil))bis(etan-2,1-diil))bis(biciklo[2.2.1]heptan-1-karboksilna kiselina); 4-((2-((3'-(5-(2-(4-karboksibiciklo[2.2.1]heptan-1-il)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)metil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(karboksimetil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(3-karboksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(karboksi-2-metilpropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-((1-karboksiciklopropil)metil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-((2-((3'-(5-(2-(4-karboksibiciklo[2.2.1]heptan-1-il)etil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)metil)biciklo[2.2.2]oktan-1-karboksilna kiselina; 3-((2-((3'-(5-(2-(4-karboksibiciklo[2.2.1]heptan-1-il)etil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)metil)biciklo[1.1.1]pentan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(4-karboksifenetil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 5-((2-((3'-(5-(2-(4-karboksibiciklo[2.2.1]heptan-1-il)etil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)metil)biciklo-1H-pirazol-3-karboksilna kiselina; 4-(2-(2-((2-kloro-2'-metil-3'-(1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2-kloro-2'-metil-3'-(1-metil-5-(tetrahidro-2H-piran-4-il)-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2-kloro-2'-metil-3'-(1,5-dimetil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2'-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(1-karbamoilpiperidin-4-il)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2-kloro-2'-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (R)-4-(2-(2-((2-kloro-3'-(5-(2-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2'-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (S)-4-(2-(2-((2-kloro-3'-(5-(2-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2'-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2-kloro-3'-(5-(2-hidroksietil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2'-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4,4'-(((((2-kloro-2'-metil-[1,1'-bifenil]-3,3'-diil)bis(azandiil))bis(karbonil))bis(1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-2,5-diil))bis(etan-2,1-diil))bis(biciklo[2.2.1]heptan-1-karboksilna kiselina); 4-((2-((3'-(5-(2-(4-karboksibiciklo[2.2.1]heptan-1-il)etil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2'-kloro-2-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)metil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(4-karboksifenetil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2-kloro-2'-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2'-kloro-2-metil-3'-(1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2'-kloro-2-metil-3'-(1-metil-5-(tetrahidro-2H-piran-4-il)-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2'-kloro-3'-(1,5-dimetil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(1-karbamoilpiperidin-4-il)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2'-kloro-2-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (R)-4-(2-(2-((2'-kloro-3'-(5-(2-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (S)-4-(2-(2-((2'-kloro-3'-(5-(2-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2'-kloro-3'-(5-(2-hidroksietil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-((2-((3'-(5-(2-(4-karboksibiciklo[2.2.1]heptan-1-il)etil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2-kloro-2'-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)metil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(4-karboksifenetil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2'-kloro-2-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2-kloro-2'-cijano-3'-(1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2-kloro-2'-cijano-3'-(1-metil-5-(tetrahidro-2H-piran-4-il)-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2-kloro-2'-cijano-3'-(1,5-dimetil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (R)-4-(2-(2-((2-kloro-2'-cijano-3'-(5-(2-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2-kloro-2'-cijano-3'-(5-(2-hidroksietil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4,4'-(((((2-kloro-2'-cijano-[1,1'-bifenil]-3,3'-diil)bis(azandiil))bis(karbonil))bis(1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-2,5-diil))bis(etan-2,1-diil))bis(biciklo[2.2.1]heptan-1-karboksilna kiselina); 4-((2-((3'-(5-(2-(4-karboksibiciklo[2.2.1]heptan-1-il)etil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2'-kloro-2-cijano-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)metil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dimetil-3'-(1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4,4'-(((((2,2'-dimetil-[1,1'-bifenil]-3,3'-diil)bis(azandiil))bis(karbonil))bis(1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-2,5-diil))bis(etan-2,1-diil))bis(biciklo[2.2.1]heptan-1-karboksilna kiselina); 4-((2-((3'-(5-(2-(4-karboksibiciklo[2.2.1]heptan-1-il)etil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dimetil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)metil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dimetil-3'-(1-metil-5-(tetrahidro-2H-piran-4-il)-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (R)-4-(2-(2-((3'-(5-(2-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dimetil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (S)-4-(2-(2-((3'-(5-(2-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dimetil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(2-hidroksietil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dimetil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(5-(4-hidroksicikloheksil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; i 4-(2-(2-((2-kloro-3'-(5-(4-hidroksicikloheksil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2'-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; ili njihova farmaceutski prihvatljiva sol; ili (b) 4-(2-(2-((3'-(5-(2-(trans-4-karboksicikloheksil)etil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(4-karboksibutil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(5-(5-(dimetilamino)-5-oksopentil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(cis-4-karboksi-4-metilcikloheksil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; i 4-(2-(2-((3'-(5-(trans-4-karboksi-4-metilcikloheksil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; ili njihova farmaceutski prihvatljiva sol.
10. Spoj prema patentnom zahtjevu 1, naznačen time, da je 4,4'-(((((2-kloro-2'-metil-[1,1'-bifenil]-3,3'-diil)bis(azandiil))bis(karbonil))bis(1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-2,5-diil))bis(etan-2,1-diil))bis(biciklo[2.2.1]heptan-1-karboksilna kiselina), ili njezina farmaceutski prihvatljiva sol.
11. Spoj prema patentnom zahtjevu 1, naznačen time, da je 4,4'-(((((2,2'-dikloro-[1,1'-bifenil]-3,3'-diil)bis(azandiil))bis(karbonil))bis(1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-2,5-diil))bis(etan-2,1-diil))bis(biciklo[2.2.1]heptan-1-karboksilna kiselina), ili njezina farmaceutski prihvatljiva sol.
12. Spoj prema patentnom zahtjevu 1, naznačen time, da je 4-((2-((3'-(5-(2-(4-karboksibiciklo[2.2.1]heptan-1-il)etil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)metil)biciklo[2.2.1]heptan-1-karboksilna kiselina, ili njezina farmaceutski prihvatljiva sol.
13. Spoj prema patentnom zahtjevu 1, naznačen time, da je 4,4'-(((((2-kloro-2'-cijano-[1,1'-bifenil]-3,3'-diil)bis(azandiil))bis(karbonil))bis(1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-2,5-diil))bis(etan-2,1-diil))bis(biciklo[2.2.1]heptan-1-karboksilna kiselina), ili njezina farmaceutski prihvatljiva sol.
14. Farmaceutski pripravak, naznačen time, da sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 8, ili njegovu farmaceutski prihvatljivu sol ili njegov stereoizomer, ili spoj prema bilo kojem od patentnih zahtjeva 9 do 13, ili njegovu farmaceutski prihvatljivu sol, te farmaceutski prihvatljivo pomoćno sredstvo ili nosač.
15. Spoj prema bilo kojem od patentnih zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, ili spoj prema bilo kojem od patentnih zahtjeva 9 do 13, ili njegova farmaceutski prihvatljiva sol, naznačen time, da je za uporabu u inhibiranju interakcije PD-1/PD-L1.
16. Spoj prema bilo kojem od patentnih zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, ili spoj prema bilo kojem od patentnih zahtjeva 9 do 13, ili njegova farmaceutski prihvatljiva sol, naznačen time, da je za uporabu u liječenju bolesti ili poremećaja koji su povezani s inhibiranjem interakcije PD-1/PD-L1.
17. Spoj, sol, ili stereoizomer za uporabu prema patentnom zahtjevu 16, naznačen time, da se kod bolesti ili poremećaja radi o zaraznoj bolesti, upali, autoimunoj bolesti, raku, ili neurodegenerativnom poremećaju.
18. Spoj, sol, ili stereoizomer za uporabu prema patentnom zahtjevu 16, naznačen time, da se kod bolesti ili poremećaja radi o raku.
19. Spoj, sol ili stereoizomer za uporabu prema patentnom zahtjevu 18, naznačen time, da: (a) rak se bira od sljedećih: rak kostiju, rak gušterače, rak kože, rak glave i vrata, kožni maligni melanom, očni maligni melanom, rak maternice, rak jajnika, rak rektuma, rak analne regije, rak abdomena, rak testisa, karcinom falopijevih cijevi, rak endometrija, karcinom cerviksa, karcinom vagine, karcinom vulve, ne-Hodgkinov limfom, rak jednjaka, rak malog crijeva, rak endokrinog sustava, rak tiroidne žlijezde, rak paratiroidne žlijezde, rak adrenalne žlijezde, sarkom mekog tkiva, rak uretre, rak penisa, kronične ili akutne leukemije, solidni tumori u djetinjstvu, limfom limfocita, rak mokraćnog mjehura, rak bubrega, karcinom bubrežne zdjelice, neoplazma središnjeg živčanog sustava (CNS), primarni limfom središnjeg živčanog sustava (CNS), tumorska angiogeneza, tumor kralježnice, gliom moždanog debla, pituitarni adenom, Kaposijev sarkom, epidermoidni rak, rak rožnatih stanica, limfom T stanica, vrste raka koje su inducirane okolišem uključujući one koje su inducirane azbestom, melanom, metastatski maligni melanom, rak bubrega, karcinom svijetlih bubrežnih stanica, rak prostate, adenokarcinom prostate koji je hormonski otporan, rak dojke, rak debelog crijeva, rak pluća, rak rožnatih stanica glave i vrata, urotelni rak, vrste raka s velikom mikrosatelitskom nestabilnošću (MSIhigh), solidni tumori, solidni tumori raka prostate, solidni tumori raka debelog crijeva, solidni tumori raka jednjaka, solidni tumori raka endometrija, solidni tumori raka bubrega, solidni tumori raka jetre, solidni tumori raka gušterače, solidni tunori raka želuca, solidni tumori raka dojke, solidni tumori raka pluća, solidni tumori raka glave i vrata, solidni tumori tiroidnog raka, solidni tumori glioblastoma, solidni tumori sarkoma, solidni tumori raka mokraćnog mjehura, povratni ne-Hodgkinov limfom, uporni ne-Hodgkinov limfom, periodični folikularni ne-Hodgkinov limfom, Hodgkinov limfom, holangiokarcinom, rak žučnih vodova, rabdomiosarkom, leiomiosarkom, hepatocelularni karcinom, Ewingov sarkom, rak mozga, tumor mozga, astrocitom, neuroblastom, karcinom bazalnih stanica, hondrosarkom, epitelni sarkom, rak oka, gastrointestinalni rak, gastrointestinalni stromalni tumori, leukemija kosmatih stanica, intestinalni rak, rak otočićkih stanica, oralni rak, rak usta, rak grla, rak grkljana, rak usne, mezoteliom, rak vrata, rak nosne šupljine, okularni rak, okularni melanom, rak karlice, karcinom renalnih stanica, rak žlijezde slinovnice, rak sinusa, rak kičme, rak jezika, tubularni karcinom, rak mokraćnih kanala, vrste raka genitourinarnog trakta, vrste raka živčanog sustava, hematološke vrste raka, hematološki limfomi, hematološke leukemije, akutna limfoblastična leukemija (ALL), akutna mijeloična leukemija (AML), akutna promijelocitna leukemija (APL), kronična limfocitna leukemija (CLL), kronična mijeloična leukemija (CML), difuzni limfom velikih B stanica (DLBCL), limfom plaštenih stanica, mijeloproliferativne bolesti, primarna mijelofibroza (PMF), policitemija vera (PV), esencijalna trombocitoza (ET), sindrom mijelodisplazije (MDS), akutni limfoblastični limfom T stanica (T-ALL), multipli mijelom (MM), sarkomi, osteosarkomi, angiosarkomi, fibrosarkomi, liposarkomi, miksomi, rabdomiom, rabdosarkom, fibrom, lipom, harmatom, teratom, rak ne-malih stanica pluća (NSCLC), rak malih stanica pluća, bronhogeni karcinom, bronhogeni sarkom rožnatih stanica, bronhogeni karcinom nediferenciranih malih stanica, bronhogeni karcinom nediferenciranih velikih stanica, bronhogeni adenokarcinom, alveolni (bronhijalni) karcinom, bronhijalni adenom, hondromatozni hamartom, karcinom rožnatih stanica jednjaka, adenokarcinom jednjaka, leiomiosarkom jednjaka, limfom jednjaka, karcinom abdomena, limfom abdomena, leiomiosarkom abdomena, duktalni adenokarcinom, inzulinom, glukagonom, gastrinom, karcinoidni tumori gušterače, vipom, vrste raka malog crijeva, adenokarcinom malog crijeva, limfom malog crijeva, karcionidni tumori malog crijeva, leiomiom malog crijeva, hemangiom malog crijeva, lipom malog crijeva, neurofibrom malog crijeva, fibrom malog crijeva, vrste raka velikog crijeva, adenokarcinom velikog crijeva, tubularni adenom velikog crijeva, vilozni adenom velikog crijeva, hamartom velikog crijeva, leiomiom velikog crijeva, kolorektalni rak, adenokarcinom bubrega, Wilmov tumor (nefroblastom), karcinom rožnatih stanica mokraćnog mjehura, karcinom prijelaznih stanica mokraćnog mjehura, adenokarcinom mokraćnog mjehura, karcinom rožnatih stanica uretre, karcinom prijelaznih stanica uretre, adenokarcinom uretre, adenokarcinom prostate, sarkom prostate, vrste raka testisa, seminom testisa, teratom testisa, embrionalni karcinom testisa, teratokarcinom testisa, horiokarcinom testisa, sarkom testisa, karcinom intersticijskih stanica testisa, fibrom testisa, fibroadenom testisa, adenomatoidni tumori testisa, lipom testisa, vrste raka jetre, hepatom, hepatoblastom, hepatocelularni adenom, hemangiom, maligni fibrozni histiocitom, maligni limfom (sarkom retikularnih stanica), maligni tumorski hordom divovskih stanica, osteohronfrom (osteokartilagne ekstoze), benigni hondrom, hondroblastom, hondromiksofibrom, osteoidni osteom, tumori divovskih stanica, vrste raka lubanje, osteom, granulom, ksantom, osteitis deformans, meningne vrste raka, meningiom, meningiosarkom, gliomatoza, moždani astrocitom, moždani meduloblastom, moždani gliom, moždani ependimom, moždani germinom (pinealom), moždani glioblastom, multiformni moždani glioblastom, moždani oligodendrogliom, švanom mozga, moždani retinoblastom, kongenitalni tumori mozga, vrste raka kralježnice, neurofibrom kralježnice, meningiom kralježnice, gliom kralježnice, sarkom kralježnice, bolest Lhermitte-Duclos, ginekološke vrste raka, vrste raka maternice, endometrijski karcinom, predtumorna cervikalna displazija, karcinom jajnika, serozni cistadenokarcinom, mucinozni cistadenokarcinom, neklasificirani karcinom, tumori granulozno-tekalnih stanica, tumori Sertoli-Leydig stanica, disgerminom, maligni teratom, karcinom rožnatih stanica vulve, karcinom intraepitelija vulve, adenokarcinom vulve, fibrosarkom vulve, melanom vulve, karcinom svijetlih stanica vagine, karcinom rožnatih stanica vagine, botrioidni sarkom, embrionalni rabdomiosarkom, karcinom rožnatih stanica, atipičan madež displastični nevus, lipom kože, angiom, dermatofibrom, keloidi, trostruko negativni rak dojke (TNBC), i urotelni karcinom; ili (b) rak je metastatski rak koji eksprimira PD-L1; ili (c) rak je rak pluća; ili (d) rak je rak malih stanica pluća; ili (e) rak je rak ne-malih stanica pluća (NSCLC); ili (f) rak je karcinom rožnatih stanica; ili (g) rak je hepatski rak; ili (h) rak je hepatocelularni karcinom; ili (i) rak je melanom; ili (j) rak je rak mokraćnog mjehura; ili (k) rak je rak uretre; ili (l) rak je renalni rak; ili (m) rak je karcinom svijetlih bubrežnih stanica.
20. Spoj, sol ili stereoizomer za uporabu prema patentnom zahtjevu 18, naznačen time, da: (a) rak se bira od sljedećih: kožni melanom, invazivni karcinom dojke, karcinom rožnatih stanica glave i vrata, nemišićni invazivni rak mokraćnog mjehura (NMIBC), rak žučnog trakta, rak rožnatih stanica ne-malih stanica pluća (NSCLC), karcinom jednjaka, adenokarcinom abdomena, kolorektalni adenokarcinom, urološke vrste raka, papilarni karcinom bubrega, rak zametnih stanica testisa, karcinom hromofobnih bubrežnih stanica, serozni adenokarcinom, i karcinom kožnih rožnatih stanica; ili (b) rak je karcinom kožnih rožnatih stanica.
21. Spoj prema bilo kojem od patentnih zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, ili spoj prema bilo kojem od patentnih zahtjeva 9 do 13, ili njegova farmaceutski prihvatljiva sol, naznačen time, da je za uporabu u poboljšavanju, pospješivanju i/ili povećavanju imunosnog odgovora kod pacijenta.
HRP20230306TT 2018-05-11 2019-05-10 Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori HRP20230306T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862670249P 2018-05-11 2018-05-11
US201862688164P 2018-06-21 2018-06-21
EP19725627.4A EP3790877B1 (en) 2018-05-11 2019-05-10 Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
PCT/US2019/031728 WO2019217821A1 (en) 2018-05-11 2019-05-10 Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators

Publications (1)

Publication Number Publication Date
HRP20230306T1 true HRP20230306T1 (hr) 2023-05-12

Family

ID=66625434

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20230306TT HRP20230306T1 (hr) 2018-05-11 2019-05-10 Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori

Country Status (31)

Country Link
US (4) US10618916B2 (hr)
EP (2) EP3790877B1 (hr)
JP (2) JP7328995B2 (hr)
KR (1) KR20210018282A (hr)
CN (1) CN112752756B (hr)
AU (2) AU2019267824B2 (hr)
BR (1) BR112020022936A2 (hr)
CA (1) CA3099994A1 (hr)
CL (2) CL2020002922A1 (hr)
CO (1) CO2020015437A2 (hr)
CR (1) CR20200614A (hr)
DK (1) DK3790877T3 (hr)
EC (1) ECSP20079887A (hr)
ES (1) ES2943028T3 (hr)
FI (1) FI3790877T3 (hr)
HR (1) HRP20230306T1 (hr)
HU (1) HUE061503T2 (hr)
JO (1) JOP20200288A1 (hr)
LT (1) LT3790877T (hr)
MD (1) MD3790877T2 (hr)
MX (2) MX2020012045A (hr)
PE (1) PE20211918A1 (hr)
PH (1) PH12020551927A1 (hr)
PL (1) PL3790877T3 (hr)
PT (1) PT3790877T (hr)
RS (1) RS64188B1 (hr)
SA (1) SA520420524B1 (hr)
SG (1) SG11202011165TA (hr)
SI (1) SI3790877T1 (hr)
TW (2) TW202425987A (hr)
WO (1) WO2019217821A1 (hr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Fgfr抑制剤としての二環式複素環
WO2016134320A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
HRP20221035T1 (hr) 2015-11-19 2022-11-11 Incyte Corporation Heterociklički spojevi kao imunomodulatori
PE20230731A1 (es) 2015-12-22 2023-05-03 Incyte Corp Compuestos heterociclicos como inmunomoduladores
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
TWI771305B (zh) 2016-06-20 2022-07-21 美商英塞特公司 作為免疫調節劑之雜環化合物
EP3474845B1 (en) 2016-06-27 2024-03-20 ChemoCentryx, Inc. Immunomodulator compounds
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
PE20200005A1 (es) 2016-12-22 2020-01-06 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1
WO2018119266A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
WO2018200571A1 (en) 2017-04-25 2018-11-01 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1h-indene analogs and methods using same
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
IL272258B (en) 2017-07-28 2022-08-01 Chemocentryx Inc Immunomodulator compounds
US10392405B2 (en) 2017-08-08 2019-08-27 Chemocentryx, Inc. Macrocyclic immunomodulators
AU2019222644B2 (en) 2018-02-13 2021-04-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10568874B2 (en) 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
IL303087B1 (en) 2018-02-27 2024-08-01 Incyte Corp Midazopyrimidines and triazolopyrimidines as A2A /A2B inhibitors
US12083118B2 (en) 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
FI3774791T3 (fi) 2018-03-30 2023-03-21 Incyte Corp Heterosyklisiä yhdisteitä immunomodulaattoreina
CN112041311B (zh) 2018-04-19 2023-10-03 吉利德科学公司 Pd-1/pd-l1抑制剂
DK3788047T3 (da) 2018-05-04 2024-09-16 Incyte Corp Faste former af en FGFR-inhibitor og fremgangsmåder til fremstilling deraf
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
BR112020022936A2 (pt) 2018-05-11 2021-02-02 Incyte Corporation derivados de tetra-hidro-imidazo[4,5-c]piridina como imunomoduladores de pd-l1
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
CN113166153A (zh) 2018-07-05 2021-07-23 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
EP4234030A3 (en) 2018-07-13 2023-10-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
EP3923949A1 (en) 2019-02-15 2021-12-22 Incyte Corporation Cyclin-dependent kinase 2 biomarkers and uses thereof
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
AU2020276277A1 (en) 2019-05-15 2021-12-09 Chemocentryx, Inc. Triaryl compounds for treatment of PD-L1 diseases
KR20220024701A (ko) 2019-06-20 2022-03-03 케모센트릭스, 인크. Pd-l1 질환의 치료를 위한 화합물
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
JP7559059B2 (ja) 2019-09-30 2024-10-01 インサイト・コーポレイション 免疫調節剤としてのピリド[3,2-d]ピリミジン化合物
PE20221905A1 (es) 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
MX2022004513A (es) 2019-10-14 2022-07-19 Incyte Corp Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
MX2022004450A (es) 2019-10-16 2022-05-03 Chemocentryx Inc Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11713307B2 (en) 2019-10-16 2023-08-01 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
MX2022005651A (es) * 2019-11-11 2022-07-27 Incyte Corp Sales y formas cristalinas de un inhibidor de la proteina de muerte celular programada 1 (pd-1)/ligando de muerte celular programada 1 (pd-l1).
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Fgfr阻害剤としての三環式複素環
CN115279766A (zh) 2020-01-03 2022-11-01 因赛特公司 包含a2a/a2b和pd-1/pd-l1抑制剂的组合疗法
JP2023509155A (ja) * 2020-01-03 2023-03-07 上▲海▼翰森生物医▲薬▼科技有限公司 ビフェニル系誘導体阻害剤、その調製方法及び使用
WO2021139647A1 (zh) * 2020-01-07 2021-07-15 上海和誉生物医药科技有限公司 一种联苯基氟代双键衍生物及其制备方法和在药学上的应用
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4114401A1 (en) 2020-03-06 2023-01-11 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
EP4135844A1 (en) 2020-04-16 2023-02-22 Incyte Corporation Fused tricyclic kras inhibitors
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
WO2021254005A1 (zh) * 2020-06-17 2021-12-23 上海和誉生物医药科技有限公司 一种免疫抑制剂、其制备方法和应用
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
CN114698376B (zh) 2020-10-29 2022-10-18 深圳微芯生物科技股份有限公司 作为免疫调节剂的联苯类化合物及其制备方法和应用
KR20230117573A (ko) 2020-11-06 2023-08-08 인사이트 코포레이션 Pd-1 및 pd-l1 억제제, 및 이의 염 및 결정형의 제조 방법
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Pd—1/pd—l1抑制劑之結晶形式
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
JP2024502005A (ja) 2020-12-29 2024-01-17 インサイト・コーポレイション A2a/a2b阻害剤、pd-1/pd-l1阻害剤、及び抗cd73抗体を含む併用療法
CN116710460A (zh) * 2021-01-18 2023-09-05 上海齐鲁制药研究中心有限公司 联苯衍生物及其应用
KR20230141812A (ko) * 2021-02-01 2023-10-10 쉔젠 칩스크린 바이오사이언스 씨오., 엘티디. 면역 조절제로서의 바이페닐 화합물, 이의 제조방법 및 용도
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
TW202317565A (zh) 2021-07-07 2023-05-01 美商英塞特公司 作為kras抑制劑的三環化合物
JP2024529347A (ja) 2021-07-14 2024-08-06 インサイト・コーポレイション Krasの阻害剤としての三環式化合物
EP4396187A1 (en) 2021-08-31 2024-07-10 Incyte Corporation Naphthyridine compounds as inhibitors of kras
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
US20230149409A1 (en) * 2021-09-24 2023-05-18 Incyte Corporation Treatment of human papillomavirus-associated cancers by pd-l1 inhibitors
JP2024537824A (ja) 2021-10-01 2024-10-16 インサイト・コーポレイション ピラゾロキノリンkras阻害剤
IL312114A (en) 2021-10-14 2024-06-01 Incyte Corp Quinoline compounds as Kras inhibitors
TW202320792A (zh) 2021-11-22 2023-06-01 美商英塞特公司 包含fgfr抑制劑及kras抑制劑之組合療法
CN114209815B (zh) * 2021-11-22 2024-04-26 山东大学 一种药物组合物及其制备方法和应用
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
AR128043A1 (es) 2021-12-22 2024-03-20 Incyte Corp Sales y formas sólidas de un inhibidor de fgfr y procesos para su preparación
WO2023207933A1 (zh) * 2022-04-26 2023-11-02 深圳微芯生物科技股份有限公司 一种作为免疫调节剂的联苯类化合物的晶型及其制备方法
TW202346308A (zh) * 2022-04-26 2023-12-01 大陸商深圳微芯生物科技股份有限公司 作為免疫調節劑的聯苯類化合物的鹽型、晶型及其製備方法
US20230399342A1 (en) 2022-06-08 2023-12-14 Incyte Corporation Tricyclic triazolo compounds as dgk inhibitors
US20240101557A1 (en) 2022-07-11 2024-03-28 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
TW202428272A (zh) 2022-11-18 2024-07-16 美商英塞特公司 作為dgk抑制劑之雜芳基氟烯烴
TW202428575A (zh) 2023-01-12 2024-07-16 美商英塞特公司 作為dgk抑制劑之雜芳基氟代烯烴
WO2024196989A1 (en) * 2023-03-20 2024-09-26 University Of Central Florida Research Foundation, Inc. Anti-malarial therapy

Family Cites Families (333)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3272781A (en) 1963-08-07 1966-09-13 American Potash & Chem Corp Boroureas of phosphinoborine polymers
FR1425700A (fr) 1965-02-22 1966-01-24 Basf Ag Composés formant des complexes métalliques et procédé pour les préparer et les utiliser
US4208328A (en) 1978-04-27 1980-06-17 General Electric Company Alkyl 3,5-dihydroxy-4-(2-benzothiazolyl)benzoates
US4789711A (en) 1986-12-02 1988-12-06 Ciba-Geigy Corporation Multifunctional epoxide resins
JPH0611031Y2 (ja) 1988-02-27 1994-03-23 タマパック株式会社 ゴルフ用パッティンググリーン
DE3828535A1 (de) 1988-08-23 1990-03-08 Basf Ag Benzimidazol-2-carbonsaeureanilide, ihre verwendung als lichtschutzmittel fuer organisches material und mit diesen aniliden stabilisiertes organisches material
US5077164A (en) 1989-06-21 1991-12-31 Minolta Camera Kabushiki Kaisha Photosensitive member containing an azo dye
DE69421982T2 (de) 1993-09-20 2000-03-30 Fuji Photo Film Co., Ltd. Positiv arbeitende Photoresistzusammensetzung
JP3461397B2 (ja) 1995-01-11 2003-10-27 富士写真フイルム株式会社 ポジ型フオトレジスト組成物
JP2001505585A (ja) 1996-12-16 2001-04-24 藤沢薬品工業株式会社 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
JPH10316853A (ja) 1997-05-15 1998-12-02 Sumitomo Bakelite Co Ltd 半導体多層配線用層間絶縁膜樹脂組成物及び該絶縁膜の製造方法
EP1019391A1 (en) 1997-10-02 2000-07-19 Merck & Co. Inc. Inhibitors of prenyl-protein transferase
WO1999044992A1 (fr) 1998-03-05 1999-09-10 Nissan Chemical Industries, Ltd. Composes d'anilide et herbicide
JP2000128987A (ja) 1998-10-28 2000-05-09 Sumitomo Bakelite Co Ltd ポリベンゾオキサゾール前駆体及びポリベンゾオキサゾール
JP2000128984A (ja) 1998-10-28 2000-05-09 Sumitomo Bakelite Co Ltd ポリベンゾオキサゾール前駆体及び樹脂
JP2000128986A (ja) 1998-10-28 2000-05-09 Sumitomo Bakelite Co Ltd ポリベンゾオキサゾール前駆体及びポリベンゾオキサゾール
US6297351B1 (en) 1998-12-17 2001-10-02 Sumitomo Bakelite Company Limited Polybenzoxazole resin and precursor thereof
EA200100675A1 (ru) 1998-12-18 2001-12-24 Аксис Фармасьютикалз, Инк. Ингибиторы протеазы
JP2000212281A (ja) 1999-01-27 2000-08-02 Sumitomo Bakelite Co Ltd ポリベンゾオキサゾ―ル前駆体及びポリベンゾオキサゾ―ル樹脂
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
JP2001114893A (ja) 1999-10-15 2001-04-24 Sumitomo Bakelite Co Ltd ポリベンゾオキサゾール樹脂およびその前駆体
US6372907B1 (en) 1999-11-03 2002-04-16 Apptera Corporation Water-soluble rhodamine dye peptide conjugates
JP2001163975A (ja) 1999-12-03 2001-06-19 Sumitomo Bakelite Co Ltd ポリベンゾオキサゾール樹脂及びその前駆体
CN1623984A (zh) 1999-12-27 2005-06-08 日本烟草产业株式会社 稠环化合物及其药物用途
DE50112961D1 (de) 2000-02-01 2007-10-18 Abbott Gmbh & Co Kg Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
ATE361297T1 (de) 2000-03-31 2007-05-15 Ortho Mcneil Pharm Inc Phenyl-substituierte imidazopyridine
EP1278734A2 (en) 2000-04-24 2003-01-29 Merck Frosst Canada & Co. Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
CZ303572B6 (cs) 2000-06-28 2012-12-12 Smithkline Beecham P. L. C. Jemne rozmelnený prostredek a zpusob jeho prípravy
WO2002014321A1 (en) 2000-08-11 2002-02-21 The Regents Of The University Of California Use of stat-6 inhibitors as therapeutic agents
AU2002224927A1 (en) 2000-12-13 2002-06-24 Basf Aktiengesellschaft Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
US6919352B2 (en) 2000-12-15 2005-07-19 Smithkline Beecham Corporation Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
SE0100567D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
AU2002258550B2 (en) 2001-03-14 2006-04-27 Eli Lilly And Company Retinoid X receptor modulators
WO2002078700A1 (en) 2001-03-30 2002-10-10 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapteutic compounds
WO2002083672A1 (en) 2001-04-10 2002-10-24 Smithkline Beecham Corporation Antiviral pyrazolopyridine compounds
JP2002316966A (ja) 2001-04-19 2002-10-31 Ueno Seiyaku Oyo Kenkyusho:Kk ビナフトール誘導体およびその製法
WO2002088124A2 (en) 2001-04-27 2002-11-07 Smithkline Beecham Corporation Pyrazolo'1,5-a!pyridine derivatives
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
EP1423389B1 (en) 2001-09-07 2007-06-06 SmithKline Beecham Corporation Pyrazolo-pyridines for the treatment of herpes infections
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
WO2003031587A2 (en) 2001-10-09 2003-04-17 The Regents Of The University Of California Use of stat-6 inhibitors as therapeutic agents
MXPA04003419A (es) 2001-10-09 2004-07-08 Upjohn Co Tetrahidro y hexahidro-carbazoles sustituidos con arilsulfonilo como ligandos del receptor 5-ht-6.
JP4024579B2 (ja) 2002-01-22 2007-12-19 住友ベークライト株式会社 プラスチック光導波路用材料及び光導波路
PL373399A1 (en) 2002-04-11 2005-08-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2003091256A1 (fr) 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Derive de pyrazolo[1,5-a]pyrimidine et inhibiteur de la nad(p)h oxydase contenant ledit derive
US20060004010A1 (en) 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
WO2004006906A2 (en) 2002-07-15 2004-01-22 Combinatorx, Incorporated Methods for the treatment of neoplasms
JP2004059761A (ja) 2002-07-30 2004-02-26 Sumitomo Bakelite Co Ltd ポリベンゾオキサゾール樹脂、その前駆体及びこれらを用いた光導波路材料並びに光導波路
US20050260126A1 (en) 2002-08-30 2005-11-24 Yukitsuka Kudo Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
JP2004091369A (ja) 2002-08-30 2004-03-25 Sumitomo Pharmaceut Co Ltd 新規ビフェニル化合物
AU2003275266A1 (en) 2002-10-03 2004-05-04 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
JP2006504755A (ja) 2002-10-15 2006-02-09 スミスクライン ビーチャム コーポレーション Gsk−3阻害薬としてのピリダジン化合物
KR100624406B1 (ko) 2002-12-30 2006-09-18 삼성에스디아이 주식회사 비페닐 유도체 및 이를 채용한 유기 전계 발광 소자
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
JP4595288B2 (ja) 2003-03-25 2010-12-08 住友ベークライト株式会社 ポリベンゾオキサゾール樹脂、その前駆体及びこれらを用いた光導波路材料並びに光導波路
BRPI0409747A (pt) 2003-04-11 2006-05-09 Glenmark Pharmaceuticals Sa novos compostos heterocìclicos úteis para tratamento de distúrbios inflamatórios e alérgicos, processo para sua preparação e composições farmacêuticas contendo estes
PE20050158A1 (es) 2003-05-19 2005-05-12 Irm Llc Compuestos inmunosupresores y composiciones
JP2005002330A (ja) 2003-05-19 2005-01-06 Sumitomo Electric Ind Ltd 光学樹脂材料、光学素子、光モジュール、フッ素化ポリマー前駆体及びフッ素化ポリマー
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US20060183746A1 (en) 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
EP1644335A4 (en) 2003-07-11 2008-06-04 Bristol Myers Squibb Co TETRAHYDROQUINOLINE DERIVATIVES COMPRISING MODULATORS OF CANNABINOID RECEPTORS
US7691870B2 (en) 2003-07-11 2010-04-06 Merck Patent Gmbh Benzimidazole carboxamides as raf kinase inhibitors
EP1661879A4 (en) 2003-08-04 2006-11-29 Ono Pharmaceutical Co A DIPHENYL ETHER COMPOUND, PROCESS FOR THE PRODUCTION AND USE THEREOF
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
JP4758349B2 (ja) 2003-10-08 2011-08-24 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
EP1679309A4 (en) 2003-10-24 2007-03-28 Ono Pharmaceutical Co ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
EP1699763A1 (de) 2003-12-23 2006-09-13 Basf Aktiengesellschaft 3-trifluormethylpicolins ureanilide und ihre verwendung als fungizide
EP1715867A4 (en) 2004-02-12 2009-04-15 Merck & Co Inc BIPYRIDYL AMIDES AS MODULATORS OF GLUTAMATE METABOTROPIC REPEATER-5
JPWO2005077948A1 (ja) 2004-02-16 2008-01-10 第一製薬株式会社 抗真菌作用複素環化合物
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
JP2005248082A (ja) 2004-03-05 2005-09-15 Sumitomo Electric Ind Ltd ポリベンゾオキサゾール樹脂前駆体の製造方法およびポリベンゾオキサゾール樹脂の製造方法
WO2005086904A2 (en) 2004-03-08 2005-09-22 Amgen Inc. Therapeutic modulation of ppar (gamma) activity
AU2005220882A1 (en) 2004-03-08 2005-09-22 Georgia State University Research Foundation, Inc Novel dicationic imidazo(1,2-a)pyridines and 5,6,7,8-tetrahydro-imidazo(1,2a)pyridines as antiprotozoal agents
US7423147B2 (en) 2004-03-31 2008-09-09 Janssen Pharmaceutical, N.V. Pyridine compounds as histamine H3 modulators
JP2005290301A (ja) 2004-04-02 2005-10-20 Sumitomo Electric Ind Ltd ポリベンゾオキサゾール樹脂前駆体の製造方法およびポリベンゾオキサゾール樹脂の製造方法
WO2005099656A2 (en) 2004-04-06 2005-10-27 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
CN1946703A (zh) 2004-04-20 2007-04-11 特兰斯泰克制药公司 取代的噻唑和嘧啶衍生物作为黑素细胞皮质激素受体调节剂
DE102004021716A1 (de) 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
EP1745036A2 (en) 2004-05-03 2007-01-24 Boehringer Ingelheim Pharmaceuticals Inc. Cytokine inhibitors
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
JP2008514611A (ja) 2004-09-23 2008-05-08 ワイス C型肝炎ウイルスによる感染を処置するためのカルバゾールおよびシクロペンタインドールの誘導体
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2006053121A2 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
DE102004054665A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
WO2006094235A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
TW200716551A (en) 2005-03-10 2007-05-01 Cgi Pharmaceuticals Inc Certain substituted amides, method of making, and method of use thereof
JP2006290883A (ja) 2005-03-17 2006-10-26 Nippon Nohyaku Co Ltd 置換ヘテロ環カルボン酸アニリド誘導体、その中間体及び農園芸用薬剤並びにその使用方法
EP1902056A2 (en) 2005-05-20 2008-03-26 Array Biopharma, Inc. Raf inhibitor compounds and methods of use thereof
US20080220968A1 (en) 2005-07-05 2008-09-11 Ge Healthcare Bio-Sciences Ab [1, 2, 4] Triazolo [1, 5-A] Pyrimidine Derivatives as Chromatographic Adsorbent for the Selective Adsorption of Igg
WO2007034282A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
ES2572263T3 (es) 2005-10-25 2016-05-31 Shionogi & Co Derivados de dihidrooxazina y tetrahidropirimidina como inhibidores de BACE 1
AU2006316322B2 (en) 2005-11-22 2011-08-25 Merck Canada Inc. Tricyclic compounds useful as inhibitors of kinases
WO2007067711A2 (en) 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
US20090281120A1 (en) 2005-12-12 2009-11-12 Ono Pharmaceutical Co., Ltd Bicyclic heterocyclic compound
US20090281075A1 (en) 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
US20090304821A1 (en) 2006-03-08 2009-12-10 Takeda Pharmaceutical Company Limited Pharmaceutical Combination
MX2008012617A (es) 2006-03-31 2008-10-10 Novartis Ag Compuestos organicos.
EP2023919A4 (en) 2006-05-08 2010-12-22 Molecular Neuroimaging Llc COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES
AU2007257959A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
EP2044061A2 (en) 2006-07-20 2009-04-08 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
DE102006035018B4 (de) 2006-07-28 2009-07-23 Novaled Ag Oxazol-Triplett-Emitter für OLED-Anwendungen
WO2008021745A2 (en) 2006-08-16 2008-02-21 Itherx Pharmaceuticals, Inc. Hepatitis c virus entry inhibitors
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制bcl蛋白質與結合夥伴間之交互作用的化合物及方法
WO2008027812A2 (en) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
CA2663178C (en) 2006-09-11 2016-01-12 Matrix Laboratories Ltd. Dibenzofuran derivatives as inhibitors of pde-4 and pde-10
AR063706A1 (es) 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ,インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
PE20081370A1 (es) 2006-09-11 2008-11-28 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
FR2906250B1 (fr) 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
MX2009004289A (es) 2006-10-27 2009-05-05 Wyeth Corp Compuestos triciclicos como inhibidores de metaloproteinasas matriciales.
EP2089364B1 (en) 2006-11-08 2013-06-12 Bristol-Myers Squibb Company Pyridinone compounds
GB0623209D0 (en) 2006-11-21 2007-01-03 F2G Ltd Antifungal agents
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
WO2008071944A1 (en) 2006-12-14 2008-06-19 Boehringer Ingelheim International Gmbh Benzoxazoles useful in the treatment of inflammation
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
EP1964840A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
JP2008218327A (ja) 2007-03-07 2008-09-18 Hitachi Ltd 電解質、電解質膜、それを用いた膜電極接合体、燃料電池電源及び燃料電池電源システム
JP2010120852A (ja) 2007-03-09 2010-06-03 Daiichi Sankyo Co Ltd 新規なジアミド誘導体
ES2388454T3 (es) 2007-03-22 2012-10-15 Astrazeneca Ab Derivados de quinolina para el tratamiento de enfermedades inflamatorias
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
ES2395583T3 (es) 2007-05-10 2013-02-13 Ge Healthcare Limited IMIDAZOL (1,2-A)PIRIDINAS y compuestos relacionados con actividad frente a los receptores cannabinoides CB2
WO2009027733A1 (en) 2007-08-24 2009-03-05 Astrazeneca Ab (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
ATE505454T1 (de) 2007-09-20 2011-04-15 Amgen Inc 1-(4-(4-benzylbenzamid)-benzyl)-azetidin-3- carboxylsäurederivate und entsprechende verbindungen als s1p-rezeptor-modulatoren zur behandlung von immunerkrankungen
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
TW200932219A (en) 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
AU2008315746A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
US7868001B2 (en) 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
CA2707491A1 (en) 2007-12-13 2009-06-18 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
RU2364597C1 (ru) 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
AU2008337876A1 (en) 2007-12-19 2009-06-25 Syngenta Participations Ag Insecticidal compounds
WO2009079683A1 (en) 2007-12-21 2009-07-02 The University Of Sydney Translocator protein ligands
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
ES2548774T3 (es) 2008-01-18 2015-10-20 Eisai R&D Management Co., Ltd. Derivado de aminodihidrotiazina condensado
JP5381718B2 (ja) 2008-01-31 2014-01-08 コニカミノルタ株式会社 ハロ多環芳香族化合物及びその製造方法
AU2009218515A1 (en) 2008-02-26 2009-09-03 Novartis Ag Heterocyclic compounds as inhibitors of CXCR2
EP2095818A1 (en) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
FR2928922B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
FR2928921B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique
FR2928924B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
JP5432982B2 (ja) 2008-03-31 2014-03-05 武田薬品工業株式会社 アポトーシスシグナル調節キナーゼ1阻害剤
KR101034351B1 (ko) 2008-05-14 2011-05-16 한국화학연구원 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물
JP5774982B2 (ja) 2008-05-19 2015-09-09 サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. イミダゾ[1,2−a]ピリジン化合物
US20110077248A1 (en) 2008-05-29 2011-03-31 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators
EP2323665B1 (en) 2008-07-24 2013-06-19 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
JP2011231017A (ja) 2008-09-09 2011-11-17 Nissan Chem Ind Ltd 光学活性エポキシ化合物及び光学活性スルホキシド化合物の製造方法、並びに該方法に用いる配位子、錯体及び該錯体の製造方法
EP2365970B1 (en) 2008-11-12 2018-03-21 Gilead Connecticut, Inc. Pyridazinones and their use as btk inhibitors
EP2376490B1 (en) 2008-12-04 2013-01-23 Proximagen Limited Imidazopyridine compounds
JP5557849B2 (ja) 2008-12-19 2014-07-23 ブリストル−マイヤーズ スクイブ カンパニー カルバゾールおよびカルボリンキナーゼ阻害剤
CN102325753B (zh) 2008-12-19 2014-09-10 百时美施贵宝公司 用作激酶抑制剂的咔唑甲酰胺化合物
AR074830A1 (es) 2008-12-19 2011-02-16 Cephalon Inc Pirrolotriazinas como inhibidores de alk y jak2
JP5624275B2 (ja) 2008-12-22 2014-11-12 ユー・ディー・シー アイルランド リミテッド 有機電界発光素子
WO2010075376A2 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
WO2010074284A1 (ja) 2008-12-26 2010-07-01 味の素株式会社 ピラゾロピリミジン化合物
JP2010202530A (ja) 2009-02-27 2010-09-16 Tokyo Institute Of Technology 含ヘテロ芳香族化合物および光学材料
KR20100101054A (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
SG10201401169QA (en) 2009-04-02 2014-05-29 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
ES2475091T3 (es) 2009-04-16 2014-07-10 Centro Nacional De Investigaciones Oncol�Gicas (Cnio) Imidazopirazinas como inhibidores de proteína cinasas
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
KR20120049852A (ko) 2009-06-30 2012-05-17 시가 테크놀로지스, 인크. 뎅기 바이러스 감염의 치료 및 예방
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
JP2011057661A (ja) 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US9095596B2 (en) 2009-10-15 2015-08-04 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
MX2012004340A (es) 2009-10-16 2012-11-23 Rib X Pharmaceuticals Inc Compuestos antimicrobianos y metodos para fabricar y utilizar los mismos.
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
EP2518072A4 (en) 2009-12-24 2014-06-04 Ajinomoto Kk IMIDAZOPYRIDAZINE COMPOUNDS
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
US20130085133A1 (en) 2010-02-08 2013-04-04 Sourthern Research Institute Office of Commercialization and Intellectual Prop. Anti-viral treatment and assay to screenfor anti-viral agent
AR080433A1 (es) 2010-03-02 2012-04-11 Merck Sharp & Dohme Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen.
KR101720824B1 (ko) 2010-03-04 2017-03-28 머크 샤프 앤드 돔 코포레이션 카테콜 o-메틸 트랜스퍼라제의 억제제 및 정신병적 장애의 치료에서의 그의 용도
EP2547678B1 (en) 2010-03-18 2016-03-16 Institut Pasteur Korea Anti-infective compounds
US8410117B2 (en) 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
WO2011159857A1 (en) 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
CN102295642B (zh) 2010-06-25 2016-04-06 中国人民解放军军事医学科学院毒物药物研究所 2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺衍生物、其制备方法及用途
EP2402345A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds
CN101891895B (zh) 2010-07-28 2011-11-30 南京航空航天大学 基于桥联双水杨醛结构的苯并噻唑类金属配位聚合物及其制法及应用
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
CN101993415B (zh) 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
WO2012047856A2 (en) 2010-10-04 2012-04-12 Institute For Hepatitis And Virus Research Novel inhibitors of secretion of hepatitis b virus antigens
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
CN103282034A (zh) 2010-11-18 2013-09-04 利亘制药公司 造血生长因子模拟物的用途
WO2012080376A1 (en) 2010-12-17 2012-06-21 Syngenta Participations Ag Insecticidal compounds
TWI617559B (zh) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 2-芳基咪唑并[1,2-b]嗒.2-苯基咪唑并[1,2-a]吡啶,和2-苯基咪唑并[1,2-a]吡衍生物
KR20140027090A (ko) 2011-01-04 2014-03-06 노파르티스 아게 연령-관련 황반 변성 (amd)의 치료에 유용한 인돌 화합물 또는 그의 유사체
CA2825098C (en) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
US8921368B2 (en) 2011-03-17 2014-12-30 Bristol-Myers Squibb Company Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012139425A1 (en) 2011-04-13 2012-10-18 Schering Corporation 5-substituted iminothiazines and their mono-and dioxides as bace inhibitors,compositions,and their use
CN102796103A (zh) 2011-05-23 2012-11-28 南京英派药业有限公司 6-(芳基甲酰)咪唑并[1,2-a]嘧啶和6-(芳基甲酰)[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用
US9278910B2 (en) 2011-05-31 2016-03-08 Receptos, Inc. GLP-1 receptor stabilizers and modulators
GB201109763D0 (en) 2011-06-10 2011-07-27 Ucl Business Plc Compounds
WO2012175991A1 (en) 2011-06-24 2012-12-27 Pharminox Limited Fused pentacyclic anti - proliferative compounds
AU2012282229B2 (en) 2011-07-08 2015-05-07 Novartis Ag Novel pyrrolo pyrimidine derivatives
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013040528A1 (en) 2011-09-16 2013-03-21 Microbiotix, Inc. Antimicrobial compounds
EP2757884B1 (en) 2011-09-22 2022-07-27 Merck Sharp & Dohme LLC Pyrazolopyridyl compounds as aldosterone synthase inhibitors
JP6040677B2 (ja) 2011-09-29 2016-12-07 東洋インキScホールディングス株式会社 太陽電池封止材用樹脂組成物
CA2851445A1 (en) 2011-10-13 2013-04-18 Novartis Ag Novel oxazine derivatives and their use in the treatment of disease
RU2014120180A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и аналоги в качестве модуляторов сиртуина
CA2852615A1 (en) 2011-10-21 2013-04-25 Torrent Pharmaceuticals Limited Novel substituted imidazopyrimidines as gpbar1 receptor modulators
WO2013120040A1 (en) 2012-02-10 2013-08-15 Children's Medical Center Corporation Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US20150011751A1 (en) 2012-03-09 2015-01-08 Carna Biosciences, Inc. Novel triazine derivative
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
ES2571479T3 (es) 2012-04-20 2016-05-25 Gilead Sciences Inc Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
US20150105433A1 (en) 2012-04-27 2015-04-16 The Uab Research Foundation TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM
WO2013191113A1 (ja) 2012-06-18 2013-12-27 住友化学株式会社 縮合複素環化合物
EP2871179A4 (en) 2012-07-03 2016-03-16 Ono Pharmaceutical Co CONNECTION WITH AGONISTIC EFFECT ON THE SOMATOSTATIN RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
EA028722B1 (ru) 2012-07-13 2017-12-29 Юсб Байофарма Спрл Производные имидазопиридина в качестве модуляторов активности tnf
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
JP2015178457A (ja) 2012-07-25 2015-10-08 杏林製薬株式会社 ピラゾロピリジン誘導体、またはその薬理学的に許容される塩
US9428511B2 (en) 2012-09-06 2016-08-30 Bristol-Myers Squibb Company Imidazopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
WO2014048939A1 (en) 2012-09-26 2014-04-03 F. Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
WO2014061693A1 (ja) 2012-10-17 2014-04-24 塩野義製薬株式会社 新規非芳香族炭素環又は非芳香族複素環誘導体
US9163027B2 (en) 2012-11-21 2015-10-20 Stategics, Inc. Substituted triazolo-pyrimidine compounds for modulating cell proliferation differentiation and survival
JP6037804B2 (ja) 2012-12-03 2016-12-07 富士フイルム株式会社 ガス分離膜
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
JP2016505055A (ja) 2013-01-22 2016-02-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Bace1阻害剤としてのフルオロ−[1,3]オキサジン
CN103933036B (zh) 2013-01-23 2017-10-13 中国人民解放军军事医学科学院毒物药物研究所 2‑芳基咪唑并[1,2‑α]吡啶‑3‑乙酰胺衍生物在制备防治PTSD的药物中的用途
EP2950814A4 (en) 2013-01-31 2016-06-08 Univ Jefferson PD-L1 AND PD-L2 BASED FUSION PROTEINS AND USES THEREOF
EP2963037B1 (en) 2013-02-27 2019-03-27 Mochida Pharmaceutical Co., Ltd. Novel pyrazole derivative
SG11201507196WA (en) 2013-03-08 2015-10-29 Amgen Inc Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
CN104045552B (zh) 2013-03-13 2019-06-11 江苏先声药业有限公司 作为神经保护剂的药用化合物
JP2016516399A (ja) 2013-03-13 2016-06-09 オーストラリアン ニュークリア サイエンス アンド テクノロジー オーガニゼーション 非機能性tspo遺伝子を有するトランスジェニック非ヒト生物
US9527842B2 (en) 2013-03-14 2016-12-27 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CA2902594C (en) 2013-03-14 2023-01-10 Curadev Pharma Private Ltd. Inhibitors of the kynurenine pathway
DK2968304T3 (en) 2013-03-14 2019-01-28 Univ Columbia 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE.
EP2968265A4 (en) 2013-03-14 2016-12-28 Celtaxsys Inc INHIBITORS OF THE LEUKOTRIEN A4 HYDROLASE
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
NZ754039A (en) 2013-06-26 2021-06-25 Abbvie Inc Primary carboxamides as btk inhibitors
MX2015017821A (es) 2013-07-02 2016-04-15 Syngenta Participations Ag Heterociclos bi-o triciclicos activos como plaguicidas con sustituyentes que contienen azufre.
TWI641595B (zh) 2013-07-17 2018-11-21 日商大塚製藥股份有限公司 氰基三唑化合物類
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
EP2835375A1 (en) 2013-08-09 2015-02-11 Fundació Institut Català d'Investigació Química Bis-salphen compounds and carbonaceous material composites comprising them
KR101715090B1 (ko) 2013-08-28 2017-03-13 한국화학연구원 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물
BR112016004194A8 (pt) 2013-09-04 2020-02-11 Bristol Myers Squibb Co compostos úteis como imunomoduladores
HUE038169T2 (hu) 2013-09-06 2018-09-28 Aurigene Discovery Tech Ltd 1,2,4-Oxadiazol származékok mint immunomodulátorok
KR20160081898A (ko) 2013-09-06 2016-07-08 오리진 디스커버리 테크놀로지스 리미티드 면역조절제로서 1,3,4-옥사디아졸 및 1,3,4-티아디아졸 유도체
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
JP6336870B2 (ja) 2013-09-30 2018-06-06 日本ポリプロ株式会社 ビフェノール化合物及びそれを用いるオレフィン重合用触媒並びにオレフィン重合体の製造方法
FR3012140B1 (fr) 2013-10-18 2016-08-26 Arkema France Unite et procede pour la purification de methacrylate de methyle brut
GB201321736D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321733D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015095337A2 (en) 2013-12-18 2015-06-25 The Rockefeller University PYRAZOLO[1,5-a]PYRIMIDINECARBOXAMIDE DERIVATIVES FOR TREATING COGNITIVE IMPAIRMENT
RU2016131792A (ru) 2014-01-03 2018-02-06 Байер Энимэл Хельс ГмбХ Новые пиразолил-гетероариламиды в качестве средств для борьбы с вредителями
CA2938152A1 (en) 2014-02-10 2015-08-13 Merck Sharp & Dohme Corp. Antibodies that bind to human tau and assay for quantifying human tau using the antibodies
PT3110418T (pt) 2014-02-25 2020-01-22 Achillion Pharmaceuticals Inc Compostos de arilo, heteroarilo e heterocíclicos para tratamento de distúrbios mediados por complemento
JP6490464B2 (ja) 2014-03-26 2019-03-27 三井化学株式会社 遷移金属化合物、オレフィン重合用触媒およびオレフィン系重合体の製造方法
WO2015150097A1 (en) 2014-04-04 2015-10-08 Iomet Pharma Ltd Indole derivatives for use in medicine
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
CN106065009B (zh) 2014-06-28 2019-03-01 广东东阳光药业有限公司 作为丙型肝炎抑制剂的化合物及其在药物中的应用
CN104211726B (zh) 2014-08-11 2017-06-16 中南民族大学 非茂类三齿双核钛配合物、制备方法及用途
US20170305922A1 (en) 2014-09-17 2017-10-26 Epizyme, Inc. Carm1 inhibitors and uses thereof
EP3194368B1 (en) 2014-09-19 2020-12-23 MacKay Medical Foundation the Presbyterian Church in Taiwan MacKay Memorial Hospital Benzo-heterocyclic compounds and their applications
AU2015328285B2 (en) 2014-10-06 2019-07-18 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
AU2015360416A1 (en) 2014-12-10 2017-06-08 Massachusetts Institute Of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
JP6853619B2 (ja) 2015-01-16 2021-03-31 大塚製薬株式会社 シアノトリアゾール化合物の医薬用途
DE112016000383A5 (de) 2015-01-20 2017-10-05 Cynora Gmbh Organische Moleküle, insbesondere zur Verwendung in optoelektronischen Bauelementen
WO2016118404A1 (en) 2015-01-20 2016-07-28 Merck Sharp & Dohme Corp. Iminothiadiazine dioxides bearing an amine-linked substituent as bace inhibitors, compositions, and their use
WO2016156282A1 (en) 2015-04-02 2016-10-06 Bayer Cropscience Aktiengesellschaft Novel triazole compounds for controlling phytopathogenic harmful fungi
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017070320A1 (en) 2015-10-21 2017-04-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Phenyl indole allosteric inhibitors of p97 atpase
KR101717601B1 (ko) 2015-11-10 2017-03-20 한국화학연구원 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물
HRP20221035T1 (hr) 2015-11-19 2022-11-11 Incyte Corporation Heterociklički spojevi kao imunomodulatori
US20170174671A1 (en) 2015-12-17 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
CN108463109B (zh) 2015-12-22 2022-04-29 先正达参股股份有限公司 杀有害生物活性吡唑衍生物
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
PE20230731A1 (es) 2015-12-22 2023-05-03 Incyte Corp Compuestos heterociclicos como inmunomoduladores
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
AU2016378482A1 (en) 2015-12-22 2018-07-12 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
KR101653560B1 (ko) 2016-02-02 2016-09-12 한국화학연구원 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
TWI771305B (zh) 2016-06-20 2022-07-21 美商英塞特公司 作為免疫調節劑之雜環化合物
MX2018016331A (es) 2016-06-20 2019-05-20 Novartis Ag Formas cristalinas de compuesto de triazolopirimidina.
MX2018016295A (es) 2016-06-20 2019-09-16 Elanco Us Inc Interferon porcino pegilado y metodos de utilizacion del mismo.
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3493804A1 (en) * 2016-08-03 2019-06-12 Arising International, Inc. Symmetric or semi-symmetric compounds useful as immunomodulators
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
CN110167560B (zh) 2016-08-30 2023-08-18 四相制药公司 四环素化合物和治疗方法
KR102559851B1 (ko) 2016-12-21 2023-07-25 아세르타 파마. 비.브이. 브루톤 티로신 키나제의 이미다조피라진 저해제
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
PE20200005A1 (es) * 2016-12-22 2020-01-06 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1
WO2018119266A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119221A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
SI3559009T1 (sl) 2016-12-22 2021-08-31 Calithera Biosciences, Inc. Sestavki in postopki za zaviranje arginazne dejavnosti
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
IL272258B (en) 2017-07-28 2022-08-01 Chemocentryx Inc Immunomodulator compounds
US10392405B2 (en) 2017-08-08 2019-08-27 Chemocentryx, Inc. Macrocyclic immunomodulators
CN109400522B (zh) 2017-08-18 2023-04-28 上海轶诺药业有限公司 一种具有pd-l1抑制活性的化合物、其制备方法及用途
FI3774791T3 (fi) 2018-03-30 2023-03-21 Incyte Corp Heterosyklisiä yhdisteitä immunomodulaattoreina
WO2019192506A1 (en) 2018-04-03 2019-10-10 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
CN112041311B (zh) 2018-04-19 2023-10-03 吉利德科学公司 Pd-1/pd-l1抑制剂
BR112020022936A2 (pt) 2018-05-11 2021-02-02 Incyte Corporation derivados de tetra-hidro-imidazo[4,5-c]piridina como imunomoduladores de pd-l1
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20210089195A (ko) 2018-11-02 2021-07-15 상하이 맥시노벨 파마수티컬스 씨오., 엘티디. 비페닐계 화합물, 이의 중간체, 제조 방법, 약학 조성물 및 용도
WO2020156323A1 (en) 2019-01-31 2020-08-06 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
JP7559059B2 (ja) 2019-09-30 2024-10-01 インサイト・コーポレイション 免疫調節剤としてのピリド[3,2-d]ピリミジン化合物
MX2022005651A (es) 2019-11-11 2022-07-27 Incyte Corp Sales y formas cristalinas de un inhibidor de la proteina de muerte celular programada 1 (pd-1)/ligando de muerte celular programada 1 (pd-l1).

Also Published As

Publication number Publication date
PT3790877T (pt) 2023-05-10
EP3790877B1 (en) 2023-03-01
CO2020015437A2 (es) 2021-01-18
JOP20200288A1 (ar) 2020-11-11
SG11202011165TA (en) 2020-12-30
FI3790877T3 (fi) 2023-05-09
TW202425987A (zh) 2024-07-01
ES2943028T3 (es) 2023-06-08
HUE061503T2 (hu) 2023-07-28
US20190345170A1 (en) 2019-11-14
CN112752756A (zh) 2021-05-04
JP2023162216A (ja) 2023-11-08
TW201946626A (zh) 2019-12-16
US20200277309A1 (en) 2020-09-03
US11414433B2 (en) 2022-08-16
CR20200614A (es) 2021-04-27
AU2019267824A1 (en) 2021-01-07
SI3790877T1 (sl) 2023-06-30
JP2021524842A (ja) 2021-09-16
ECSP20079887A (es) 2021-03-31
AU2019267824B2 (en) 2023-10-05
TWI821288B (zh) 2023-11-11
MX2020012045A (es) 2021-03-29
US20220348594A1 (en) 2022-11-03
CA3099994A1 (en) 2019-11-04
KR20210018282A (ko) 2021-02-17
WO2019217821A1 (en) 2019-11-14
PE20211918A1 (es) 2021-09-28
EP3790877A1 (en) 2021-03-17
BR112020022936A2 (pt) 2021-02-02
CL2020002922A1 (es) 2021-04-16
CN112752756B (zh) 2024-06-25
DK3790877T3 (da) 2023-04-24
PH12020551927A1 (en) 2021-06-14
US20210115068A1 (en) 2021-04-22
SA520420524B1 (ar) 2024-02-15
CL2021002995A1 (es) 2022-06-24
PL3790877T3 (pl) 2023-06-12
LT3790877T (lt) 2023-05-10
US10906920B2 (en) 2021-02-02
MD3790877T2 (ro) 2023-08-31
JP7328995B2 (ja) 2023-08-17
AU2023227554A1 (en) 2023-09-28
US10618916B2 (en) 2020-04-14
MX2023013685A (es) 2024-01-08
RS64188B1 (sr) 2023-06-30
EP4219492A1 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
HRP20230306T1 (hr) Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori
HRP20221216T1 (hr) Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1
HRP20230377T1 (hr) Inhibitori mutacije kras g12c
AU2018200876B2 (en) Inhibitors of histone demethylases
CN107304191B (zh) 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
CA2472372C (en) Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
HRP20170802T1 (hr) Supstituirani triciklički benzimidazoli kao inhibitori kinaze
JPWO2021067217A5 (hr)
WO2019193541A1 (en) Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
ES2432070T3 (es) Diazaheteroarilos broncodilatadores novedosos
ES2614034T3 (es) Derivados de amidina tricíclica como inhibidores de la unión del VIH
WO2013013504A1 (zh) 替加环素衍生物
RU2011101898A (ru) Триазолпиридиновые соединения, ингибирующие jak, и способы
CA2807498A1 (en) 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof
EP3414251A1 (en) Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors
TW200817405A (en) Pyrro[1,2-b]pyridazinone compounds
RU2656209C2 (ru) Терапевтически активные производные оксазолина
ES2366629T3 (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparación y su aplicación en terapéutica.
WO2016095089A1 (en) Erk inhibitors
CA3019026A1 (en) Fused pentacyclic imidazole derivatives as modulators of tnf activity
RU2019112863A (ru) Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
US11358967B2 (en) Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma
ES2914526T3 (es) Composiciones de biarilo y métodos para modular una cascada de cinasa
WO2023164175A2 (en) Protacs of malt1
US8685982B2 (en) Thioamide, amidoxime and amidrazone derivatives as HIV attachment inhibitors